Drug Profile
DTcP-Hib vaccine - Tianjin CanSino Biotechnology
Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator Tianjin CanSino Biotechnology
- Class Bacterial vaccines; Haemophilus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Diphtheria; Haemophilus infections; Pertussis; Tetanus
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Diphtheria (In children, In infants, Prevention) in China (unspecified route) (Tianjin CanSino Biotechnology pipeline, September 2023)
- 06 Sep 2023 Discontinued - Preclinical for Haemophilus infections (In children, In infants, Prevention) in China (unspecified route) (Tianjin CanSino Biotechnology pipeline, September 2023)
- 06 Sep 2023 Discontinued - Preclinical for Pertussis (In children, In infants, Prevention) in China (unspecified route) (Tianjin CanSino Biotechnology pipeline, September 2023)